Acute Myeloblastic Leukemia Without Maturation - 182 Studies Found
Active, not recruiting |
: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay :
|
Active, not recruiting |
: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML :
|
Withdrawn |
: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|
Completed |
: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes :
|
Completed |
: Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia :
|
Completed |
: Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia :
|
Terminated |
: Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|
Completed |
: AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|
Completed |
: Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy :
|
Completed |
: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia :
|